Sjögren's disease & overlap diseases
Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study
Authors' conclusion
We found that the elevation of IFNα drives an immune endotype of Sjögren's disease, and elevated IFNα can be detected over a decade before diagnosis.
Study context
- Population
- People with Sjögren's disease in UK Primary Sjögren's Syndrome Registry (UKPSSR) (2009–2012) and people with and without Sjögren's disease in the UK Biobank Pharma Proteomics Project (2006–2010)UKPSSR
- Participants
- 177 people
- Exposure
- Elevated vs normal IFNα in Sjögren's disease
- Elevated IFNαn = 108
- Outcome
- Elevated IFNα concentrations in Sjögren's disease (UKPSSR)
Methodological detailsmulticentre observational cohort (UKPSSR), population-based cohort (UK Biobank Pharma Proteomics Project), transgenic mouse model of IFNα overexpression
- Multicentre observational cohort (UKPSSR)
- Population-based cohort (UK Biobank Pharma Proteomics Project)
- Transgenic mouse model of IFNα overexpression
Main finding
As reported in the abstract
Elevated IFNα
61%
108
Observational data: associations, not effects.
Further findings
Clinical features, elevated vs normal IFNα
- Broadly clinically similar, yet immunologically distinct
Original publication
Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study. Lancet Rheumatol. Published 2 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →